BAFF Antibody

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Tabalumab in Combination With Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma

Key Inclusion Criteria

• Have symptomatic and/or progressive multiple myeloma that was previously treated with at least 1 and no more than 3 prior lines of therapy
• Prior therapy with bortezomib is allowed if it resulted in at least a minimal response and there was no relapse or progression of multiple myeloma within 60 days of the last dose of bortezomib
• Treatment with prior autologous transplant is permitted. If a transplant is used as consolidation following chemotherapy, without intervening disease progression, it will be considered 1 line of treatment with the preceding chemotherapy

Key Exclusion Criteria

• Have had less than a minimal response or have had progressive disease within 60 days of most recent therapy with a proteasome inhibitor
• Plan to proceed to autologous transplant for consolidation after treatment on Study JDCG
• Have positive test results for human immunodeficiency virus (HIV), evidence of hepatitis B (positive for hepatitis B surface antigen, or positive for hepatitis B core antibody and negative for hepatitis B surface antibody) or positive test results of hepatits C virus (HCV; positive for anti-hepatitis C antibody)

Please visit www.clinicaltrials.gov for more information on this clinical trial [NCT01602224].